JPH10513341A - 造血幹細胞に富む組成物を得る方法、それ由来の組成物および使用法 - Google Patents
造血幹細胞に富む組成物を得る方法、それ由来の組成物および使用法Info
- Publication number
- JPH10513341A JPH10513341A JP8515883A JP51588396A JPH10513341A JP H10513341 A JPH10513341 A JP H10513341A JP 8515883 A JP8515883 A JP 8515883A JP 51588396 A JP51588396 A JP 51588396A JP H10513341 A JPH10513341 A JP H10513341A
- Authority
- JP
- Japan
- Prior art keywords
- cells
- hcc
- cell
- antibody
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/2306—Interleukin-6 (IL-6)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/20—Cytokines; Chemokines
- C12N2501/23—Interleukins [IL]
- C12N2501/235—Leukemia inhibitory factor [LIF]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2502/00—Coculture with; Conditioned medium produced by
- C12N2502/13—Coculture with; Conditioned medium produced by connective tissue cells; generic mesenchyme cells, e.g. so-called "embryonic fibroblasts"
- C12N2502/1394—Bone marrow stromal cells; whole marrow
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Developmental Biology & Embryology (AREA)
- Genetics & Genomics (AREA)
- Cell Biology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- General Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims (1)
- 【特許請求の範囲】 1.ヒト造血細胞の混合物からHCC−1エピトープに特異的な抗体を認識す る細胞(HCC−1+)を含む富化フラクションを分離することを含む、造血幹 細胞に富む組成物を得る方法。 2.幹細胞に関連する少なくとも一つの付加マーカーを発現する細胞を分離す る工程を更に含む、請求項1記載の方法。 3.付加マーカーがCD34、Thy−1+、rholo、c−kitおよび少なく とも一つの系統特異的マーカーの欠損(LIN-)からなる群から選択される、 請求項2記載の方法。 4.系統特異的マーカーがCD14、CD15、CD38、HLA−DR、C D71、CD33からなる群から選択される、請求項3記載の方法。 5.系統特異的マーカーがCD2、CD16、CD19およびグリコフォリン Aからなる群から選択される、請求項3記載の方法。 6.請求項1記載の方法により得たHCC−1+細胞の実質的に富化された集 団を含む、組成物。 7.細胞が幹細胞に関連する少なくとも一つの付加マーカーを発現する、請求 項6記載の組成物。 8.付加マーカーがCD34、Thy−1+、rholo、c−kitおよび系統特 異的マーカーの欠損(LIN-)からなる群から選択される、請求項7記載の組 成物。 9.系統特異的マーカーがCD14、CD15、CD38、HLA−DR、C D71、CD33からなる群から選択される、請求項8記載の組成物。 10.系統特異的マーカーがCD2、CD16、CD19およびグリコフォリ ンAからなる群から選択される、請求項8記載の組成物。 11.細胞がHCC−1を発現し、少なくとも一つの系統特異的マーカーを発 現しない、幹細胞に富む造血細胞を含む、組成物。 12.系統特異的マーカーがCD14およびCD15からなる群から選択され る、請求項11記載の組成物。 13.富化細胞が細胞表面マーカーCD2、CD16、CD19およびグリコ フォリンAを発現しない、請求項14記載の組成物。 14.細胞が幹細胞に関連する少なくとも一つの付加マーカーを発現する、請 求項11記載の組成物。 15.付加マーカーがCD34+、Thy−1+、rholoおよびc−kitから なる群から選択される、請求項14記載の組成物。 16.HCC−1抗体。 17.ハイブリドーマHB11729から製造されるか、またはハイブリドー マHB11729から製造された抗体と同じまたは実質的に同じ特性を有する請 求項16記載のHCC−1抗体。 18.造血幹細胞に富む細胞の組成物、例えば、請求項6−15のいずれかに 記載の組成物の製造における、請求項16または17記載のHCC−1抗体の使 用。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/340,047 US5677136A (en) | 1994-11-14 | 1994-11-14 | Methods of obtaining compositions enriched for hematopoietic stem cells, compositions derived therefrom and methods of use thereof |
US08/340,047 | 1994-11-14 | ||
PCT/IB1995/001003 WO1996015229A1 (en) | 1994-11-14 | 1995-11-13 | Methods of obtaining compositions enriched for hematopoietic stem cells, compositions derived therefrom and methods of use thereof |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH10513341A true JPH10513341A (ja) | 1998-12-22 |
JP3779323B2 JP3779323B2 (ja) | 2006-05-24 |
Family
ID=23331648
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP51588396A Expired - Fee Related JP3779323B2 (ja) | 1994-11-14 | 1995-11-13 | 造血幹細胞に富む組成物を得る方法、それ由来の組成物および使用法 |
Country Status (8)
Country | Link |
---|---|
US (1) | US5677136A (ja) |
EP (1) | EP0787181B1 (ja) |
JP (1) | JP3779323B2 (ja) |
AT (1) | ATE447009T1 (ja) |
AU (1) | AU3752795A (ja) |
CA (1) | CA2203525A1 (ja) |
DE (1) | DE69536014D1 (ja) |
WO (1) | WO1996015229A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008507957A (ja) * | 2004-07-28 | 2008-03-21 | ユニベルシテ・ルネ・デカルト・パリ 5 | 血管幹細胞及びその使用 |
Families Citing this family (136)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU768081B2 (en) * | 1996-04-03 | 2003-12-04 | Wellstat Therapeutics Corporation | Inhibitor and stimulator of stem cell proliferation and uses thereof |
AU3440797A (en) * | 1996-07-01 | 1998-01-21 | Novartis Ag | Process of obtaining compositions enriched for hematopoietic stem cells and antibodies for use therein |
AU7180398A (en) | 1996-11-13 | 1998-06-03 | Morphogenesis, Inc. | Antibody MG1 recognizing a small subset of human hematopoietic cells |
CA2274469C (en) * | 1996-12-10 | 2009-09-01 | Tony Peled | Serum-derived factor inducing cell differentiation and medical uses thereof |
EP0848012A1 (de) * | 1996-12-13 | 1998-06-17 | Roche Diagnostics GmbH | Verwendung von Polypeptiden zur Behandlung von Thrombozytopenien |
US7125714B2 (en) * | 1997-02-05 | 2006-10-24 | Licentia Ltd. | Progenitor cell materials and methods |
AU6795498A (en) * | 1997-04-08 | 1998-10-30 | Pall Corporation | Method of harvesting rare cells from blood products |
US7361336B1 (en) * | 1997-09-18 | 2008-04-22 | Ivan Bergstein | Methods of cancer therapy targeted against a cancer stem line |
US6153113A (en) * | 1999-02-22 | 2000-11-28 | Cobe Laboratories, Inc. | Method for using ligands in particle separation |
WO2001011011A2 (en) | 1999-08-05 | 2001-02-15 | Mcl Llc | Multipotent adult stem cells and methods for isolation |
US6790614B1 (en) | 1999-11-19 | 2004-09-14 | Novartis Ag | Selectable cell surface marker genes |
US7129326B2 (en) * | 2000-04-14 | 2006-10-31 | Genencor International, Inc. | Methods for selective targeting |
ES2338097T3 (es) * | 2000-04-14 | 2010-05-04 | Genencor International, Inc. | Procedimiento de identificacion selectiva. |
US6828145B2 (en) | 2000-05-10 | 2004-12-07 | Cedars-Sinai Medical Center | Method for the isolation of stem cells by immuno-labeling with HLA/MHC gene product marker |
US6632620B1 (en) | 2000-06-22 | 2003-10-14 | Andrew N. Makarovskiy | Compositions for identification and isolation of stem cells |
US20030068792A1 (en) * | 2000-12-14 | 2003-04-10 | Yiyou Chen | Targeted enzymes |
US20030049689A1 (en) * | 2000-12-14 | 2003-03-13 | Cynthia Edwards | Multifunctional polypeptides |
US20030147874A1 (en) * | 2000-12-14 | 2003-08-07 | Volker Schellenberger | Targeted enzyme prodrug therapy |
US20080248544A1 (en) * | 2000-12-14 | 2008-10-09 | Murray Christopher J | Methods And Compositions For Grafting Functional Loops Into A Protein |
US20030022249A1 (en) * | 2001-05-17 | 2003-01-30 | Juergen Schmitz | Antigen-binding fragments that recognize a subset of dendritic cells and methods of use thereof |
US7129034B2 (en) * | 2001-10-25 | 2006-10-31 | Cedars-Sinai Medical Center | Differentiation of whole bone marrow |
ATE438708T1 (de) * | 2001-11-15 | 2009-08-15 | Childrens Medical Center | Verfahren zur isolierung, expansion und differenzierung fötaler stammzellen aus chorionzotte, fruchtwasser und plazenta und therapeutische verwendungen davon |
US7625752B2 (en) * | 2001-12-21 | 2009-12-01 | Mount Sinai Hospital | Cellular compositions and methods of making and using them |
EP2107116A3 (en) | 2002-06-12 | 2009-12-09 | Genencor International, Inc. | Methods for improving a binding characteristic of a molecule |
WO2007116408A2 (en) * | 2006-04-11 | 2007-10-18 | Nanodiagnostics Israel Ltd. | Pluripotent stem cells characterized by expression of germline specific genes |
US20110158966A1 (en) * | 2002-07-23 | 2011-06-30 | Judith Seligman | Stem cells characterized by expression of germline specific genes |
CA2493768A1 (en) * | 2002-07-23 | 2004-01-29 | Nanodiagnostics, Inc. | Embryonic stem cell markers and uses thereof |
US20040028661A1 (en) * | 2002-08-07 | 2004-02-12 | Bartelmez Stephen H. | Expansion of cells using thrombopoietin and anti-transforming growth factor-beta |
ATE480550T1 (de) * | 2004-03-25 | 2010-09-15 | California Inst Of Techn | Hybridisierungskettenreaktion |
EP1756267A2 (en) | 2004-05-14 | 2007-02-28 | Becton, Dickinson and Company | Stem cell populations and methods of use |
US20080233100A1 (en) * | 2004-06-30 | 2008-09-25 | Yiyou Chen | Targeted enzymes |
SI1799844T1 (sl) * | 2004-09-10 | 2010-04-30 | Genencor Int | Postopki za detektiranje tarŽŤ |
WO2006044650A2 (en) * | 2004-10-15 | 2006-04-27 | Genencor International, Inc. | Competitive differential screening |
WO2007001420A2 (en) * | 2004-10-22 | 2007-01-04 | Genencor International, Inc. | Isolating human antibodies |
WO2006052991A2 (en) | 2004-11-11 | 2006-05-18 | The General Hosptial Corporation | Parathyroid hormone receptor activation and stem and progenitor cell expansion |
US20080044400A1 (en) * | 2004-12-09 | 2008-02-21 | Volker Schellenberger | Targeted enzyme prodrug therapy |
US7727721B2 (en) * | 2005-03-08 | 2010-06-01 | California Institute Of Technology | Hybridization chain reaction amplification for in situ imaging |
KR101004634B1 (ko) * | 2005-08-01 | 2011-01-04 | 뉴포텐셜, 인크. | 잠재력이 복원된 리프로그래밍된 세포의 제조 |
US7960357B2 (en) * | 2005-10-07 | 2011-06-14 | California Institute Of Technology | PKR activation via hybridization chain reaction |
GEP20135796B (en) | 2006-03-07 | 2013-04-10 | Compositions comprising human embryonic stem cells and their derivatives, methods of use, and methods of preparation | |
US20100172882A1 (en) * | 2007-01-11 | 2010-07-08 | Glazer Peter M | Compositions and methods for targeted inactivation of hiv cell surface receptors |
JP2010516240A (ja) | 2007-01-18 | 2010-05-20 | スオメン プナイネン リスティ,ヴェリパルベル | ヒト細胞からの新規の炭水化物、ならびにその分析および修飾のための方法 |
JP2010516239A (ja) | 2007-01-18 | 2010-05-20 | スオメン プナイネン リスティ,ヴェリパルベル | 細胞の産生に対する新規方法および試薬 |
WO2008106658A2 (en) * | 2007-03-01 | 2008-09-04 | California Institute Of Technology | TRIGGERED RNAi |
US8574567B2 (en) * | 2007-05-03 | 2013-11-05 | The Brigham And Women's Hospital, Inc. | Multipotent stem cells and uses thereof |
EP2155860B1 (en) * | 2007-05-03 | 2014-08-27 | The Brigham and Women's Hospital, Inc. | Multipotent stem cells and uses thereof |
EP2155770B1 (en) | 2007-05-16 | 2013-10-16 | California Institute of Technology | A versatile nucleic acid hairpin motif for programming biomolecular self-assembly pathways |
US8497364B2 (en) * | 2008-02-27 | 2013-07-30 | California Institute Of Technology | Triggered RNAi |
US20100021904A1 (en) * | 2008-05-21 | 2010-01-28 | Pierce Niles A | Shielded cross-linking probes |
US8241854B2 (en) * | 2008-05-22 | 2012-08-14 | California Institute Of Technology | Triggered RNAi |
US20100021901A1 (en) * | 2008-05-22 | 2010-01-28 | Peng Yin | Compositions and methods for detecting analytes |
HUE062339T2 (hu) | 2009-02-13 | 2023-10-28 | Immunomedics Inc | Sejten belül hasítható kötést tartalmazó immunkonjugátumok |
DK3329772T3 (da) | 2009-07-15 | 2020-01-27 | Calimmune Inc | Dobbeltvektor til inhibering af human immundefektvirus |
WO2011011500A1 (en) | 2009-07-21 | 2011-01-27 | Abt Holding Company | Use of stem cells to reduce leukocyte extravasation |
CN102482701B (zh) | 2009-09-16 | 2015-05-13 | 免疫医疗公司 | I类抗-cea抗体及其使用 |
WO2011053989A2 (en) | 2009-11-02 | 2011-05-05 | Yale University | Polymeric materials loaded with mutagenic and recombinagenic nucleic acids |
WO2011068845A1 (en) | 2009-12-02 | 2011-06-09 | Immunomedics, Inc. | Combining radioimmunotherapy and antibody-drug conjugates for improved cancer therapy |
SG10201907877YA (en) | 2010-02-25 | 2019-09-27 | Abt Holding Co | Modulation of macrophage activation |
WO2011133802A1 (en) | 2010-04-21 | 2011-10-27 | Helix Therapeutics, Inc. | Compositions and methods for treatment of lysosomal storage disorders |
WO2011133803A1 (en) | 2010-04-21 | 2011-10-27 | Helix Therapeutics, Inc. | Compositions and methods for targeted inactivation of hiv cell surface receptors |
US8658780B2 (en) | 2010-05-18 | 2014-02-25 | California Institute Of Technology | Triggered covalent probes for imaging and silencing genetic expression |
CA2802087A1 (en) | 2010-06-15 | 2011-12-22 | Cellular Dynamics International, Inc. | A compendium of ready-built stem cell models for interrogation of biological response |
EP2591093B1 (en) | 2010-07-07 | 2018-11-28 | FUJIFILM Cellular Dynamics, Inc. | Endothelial cell production by programming |
US8877438B2 (en) | 2010-07-20 | 2014-11-04 | California Institute Of Technology | Self-assembled polynucleotide structure |
US9834439B2 (en) | 2010-07-20 | 2017-12-05 | California Institute Of Technology | Biomolecular self-assembly |
US8962241B2 (en) | 2010-07-20 | 2015-02-24 | California Institute Of Technology | Triggered molecular geometry based bioimaging probes |
CN112516167A (zh) | 2010-08-12 | 2021-03-19 | 菲特治疗公司 | 改进的造血干细胞和祖细胞疗法 |
WO2012048276A2 (en) | 2010-10-08 | 2012-04-12 | Caridianbct, Inc. | Customizable methods and systems of growing and harvesting cells in a hollow fiber bioreactor system |
CA2826386C (en) | 2011-02-08 | 2020-04-28 | Cellular Dynamics International, Inc. | Hematopoietic precursor cell production by programming |
WO2012151199A1 (en) | 2011-05-02 | 2012-11-08 | Immunomedics, Inc. | Ultrafiltration concentration of allotype selected antibodies for small-volume administration |
SG10201914092XA (en) | 2011-06-06 | 2020-03-30 | ReGenesys BVBA | Expansion of stem cells in hollow fiber bioreactors |
ES2710452T3 (es) | 2011-06-10 | 2019-04-25 | Bluebird Bio Inc | Vectores de terapia génica para la adrenoleucodistrofia y la adrenomieloneuropatía |
EP2739735A2 (en) | 2011-08-01 | 2014-06-11 | Alnylam Pharmaceuticals, Inc. | Method for improving the success rate of hematopoietic stem cell transplants |
AU2011377617B2 (en) | 2011-09-23 | 2018-03-08 | Bluebird Bio, Inc. | Improved gene therapy methods |
IN2014CN02518A (ja) | 2011-09-30 | 2015-07-31 | Bluebird Bio Inc | |
ES2682255T3 (es) | 2011-12-02 | 2018-09-19 | Fate Therapeutics, Inc. | Métodos mejorados de tratamiento de isquemia |
US9452186B2 (en) | 2011-12-02 | 2016-09-27 | Fate Therapeutics, Inc. | Enhanced stem cell composition |
CN109513003A (zh) | 2012-08-14 | 2019-03-26 | Ibc药品公司 | 用于治疗疾病的t-细胞重定向双特异性抗体 |
CN109554350B (zh) | 2012-11-27 | 2022-09-23 | 儿童医疗中心有限公司 | 用于胎儿血红蛋白再诱导的靶向bcl11a远端调控元件 |
JP6366111B2 (ja) | 2012-12-13 | 2018-08-01 | イミューノメディクス、インコーポレイテッドImmunomedics, Inc. | 有効性の改善および毒性の減少のための、抗体およびsn−38からなるイムノコンジュゲートの投薬 |
CN105229144A (zh) | 2013-02-22 | 2016-01-06 | 细胞动力学国际有限公司 | 通过组合的遗传工程和化学工程经由正向编程产生肝细胞 |
US9943545B2 (en) | 2013-03-15 | 2018-04-17 | Fate Therapeutics, Inc. | Stem cell culture media and methods of enhancing cell survival |
US10851412B2 (en) | 2013-03-15 | 2020-12-01 | Fate Therapeutics, Inc. | Cell potency assay for therapeutic potential |
AU2014248167B2 (en) | 2013-04-03 | 2019-10-10 | FUJIFILM Cellular Dynamics, Inc. | Methods and compositions for culturing endoderm progenitor cells in suspension |
SG10201710638UA (en) | 2013-04-12 | 2018-01-30 | Saverio Lafrancesca | Improving organs for transplantation |
ES2753323T3 (es) | 2013-04-30 | 2020-04-08 | Univ Leuven Kath | Terapia celular para síndromes mielodisplásicos |
US9856472B2 (en) | 2013-07-01 | 2018-01-02 | California Institute Of Technology | Small conditional RNAs |
US9789116B2 (en) | 2013-10-15 | 2017-10-17 | Case Western Reserve University | Compositions and methods of modulating short-chain dehydrogenase activity |
WO2015073918A1 (en) | 2013-11-16 | 2015-05-21 | Terumo Bct, Inc. | Expanding cells in a bioreactor |
MX2016010683A (es) | 2014-02-21 | 2017-05-11 | Ibc Pharmaceuticals Inc | Terapia para tratar enfermedades mediante la induccion de respuesta inmune de las células que expresan trop-2. |
WO2015130416A1 (en) | 2014-02-25 | 2015-09-03 | Immunomedics, Inc. | Humanized rfb4 anti-cd22 antibody |
WO2015164228A1 (en) | 2014-04-21 | 2015-10-29 | Cellular Dynamics International, Inc. | Hepatocyte production via forward programming by combined genetic and chemical engineering |
CA2946309C (en) | 2014-04-25 | 2021-11-09 | Michael MILSOM | Synthetic bcl11a micrornas for treating hemoglobinopathies |
US10238581B2 (en) | 2014-05-09 | 2019-03-26 | Yale University | Hyperbranched polyglycerol-coated particles and methods of making and using thereof |
US11918695B2 (en) | 2014-05-09 | 2024-03-05 | Yale University | Topical formulation of hyperbranched polymer-coated particles |
CA2953567C (en) | 2014-06-24 | 2023-09-05 | Immunomedics, Inc. | Anti-histone therapy for vascular necrosis in severe glomerulonephritis |
PL3204018T3 (pl) | 2014-10-07 | 2022-01-03 | Immunomedics, Inc. | Neoadiuwantowe zastosowanie koniugatów przeciwciało-lek |
EP3770252A1 (en) | 2015-01-26 | 2021-01-27 | Fate Therapeutics, Inc. | Cells with increased immuno-regulatory properties and methods for their use and manufacture |
US9797907B2 (en) | 2015-04-22 | 2017-10-24 | Immunomedics, Inc. | Isolation, detection, diagnosis and/or characterization of circulating Trop-2-positive cancer cells |
WO2016182917A1 (en) | 2015-05-08 | 2016-11-17 | Children's Medical Center Corporation | Targeting bcl11a enhancer functional regions for fetal hemoglobin reinduction |
CN107735104B (zh) | 2015-06-25 | 2022-05-03 | 免疫医疗公司 | 组合抗hla-dr抗体或抗trop-2抗体与微管抑制剂、parp抑制剂、布鲁顿激酶抑制剂或磷酸肌醇3-激酶抑制剂使癌症治疗结果显著改善 |
EP3316885B1 (en) | 2015-07-01 | 2021-06-23 | Immunomedics, Inc. | Antibody-sn-38 immunoconjugates with a cl2a linker |
KR20180033537A (ko) | 2015-07-21 | 2018-04-03 | 더 칠드런스 메디칼 센터 코포레이션 | Pd-l1 발현 조혈 줄기 세포 및 용도 |
KR20180110112A (ko) | 2016-02-12 | 2018-10-08 | 블루버드 바이오, 인코포레이티드. | Vcn 인핸서 조성물 및 이의 사용 방법 |
US11326183B2 (en) | 2016-02-12 | 2022-05-10 | Bluebird Bio, Inc. | VCN enhancer compositions and methods of using the same |
AU2017221424A1 (en) | 2016-02-16 | 2018-09-20 | Yale University | Compositions and methods for treatment of cystic fibrosis |
JP2019508037A (ja) | 2016-02-16 | 2019-03-28 | イェール ユニバーシティーYale Universit | 標的化遺伝子編集を増強するための組成物およびその使用方法 |
DK3481843T3 (en) | 2016-07-05 | 2022-02-07 | California Inst Of Techn | Fractional initiator hybridization chain reaction |
US10815519B2 (en) | 2016-08-30 | 2020-10-27 | California Institute Of Technology | Immunohistochemistry via hybridization chain reaction |
US11690847B2 (en) | 2016-11-30 | 2023-07-04 | Case Western Reserve University | Combinations of 15-PGDH inhibitors with corticosteroids and/or TNF inhibitors and uses thereof |
WO2018145080A1 (en) | 2017-02-06 | 2018-08-09 | Case Western Reserve University | Compositions and methods of modulating short-chain dehydrogenase activity |
EP3583203B1 (en) | 2017-02-15 | 2023-11-01 | 2seventy bio, Inc. | Donor repair templates multiplex genome editing |
US11261441B2 (en) | 2017-03-29 | 2022-03-01 | Bluebird Bio, Inc. | Vectors and compositions for treating hemoglobinopathies |
WO2018187493A1 (en) | 2017-04-04 | 2018-10-11 | Yale University | Compositions and methods for in utero delivery |
AU2018261637A1 (en) | 2017-05-03 | 2019-12-12 | Biomarin Pharmaceutical Inc. | Improved lentiviruses for transduction of hematopoietic stem cells. |
WO2018218135A1 (en) | 2017-05-25 | 2018-11-29 | The Children's Medical Center Corporation | Bcl11a guide delivery |
WO2019060708A1 (en) | 2017-09-22 | 2019-03-28 | The Children's Medical Center Corporation | TREATMENT OF TYPE 1 DIABETES AND AUTOIMMUNE DISEASES OR DISORDERS |
KR20210054547A (ko) | 2018-08-31 | 2021-05-13 | 예일 유니버시티 | 삼중체 및 뉴클레아제 기반 유전자 편집을 향상시키기 위한 조성물 및 방법 |
EP3844287B1 (en) | 2018-08-31 | 2024-05-22 | Yale University | Compositions and methods for enhancing donor oligonucleotide-based gene editing |
US20210340562A1 (en) | 2018-10-19 | 2021-11-04 | Board Of Regents, The University Of Texas System | Engineered long interspersed element (line) transposons and methods of use |
MX2021005982A (es) | 2018-11-21 | 2021-09-23 | Univ Case Western Reserve | Composiciones y metodos para modular la actividad de deshidrogenasas de cadena corta. |
WO2020112195A1 (en) | 2018-11-30 | 2020-06-04 | Yale University | Compositions, technologies and methods of using plerixafor to enhance gene editing |
CA3142521A1 (en) | 2019-06-17 | 2020-12-24 | Vertex Pharmaceuticals Incorporated | Compositions and methods for editing beta-globin for treatment of hemaglobinopathies |
WO2020257779A1 (en) | 2019-06-21 | 2020-12-24 | Yale University | Hydroxymethyl-modified gamma-pna compositions and methods of use thereof |
WO2020257776A1 (en) | 2019-06-21 | 2020-12-24 | Yale University | Peptide nucleic acid compositions with modified hoogsteen binding segments and methods of use thereof |
WO2021013669A1 (en) * | 2019-07-24 | 2021-01-28 | Miltenyi Biotec B.V. & Co. KG | Assay for identifing colony-forming cells |
WO2021022161A1 (en) | 2019-07-31 | 2021-02-04 | Yale University | Compositions and methods for treating sickle cell disease |
CN115151275A (zh) | 2019-08-30 | 2022-10-04 | 耶鲁大学 | 用于向细胞递送核酸的组合物和方法 |
AU2021275122A1 (en) | 2020-05-20 | 2022-12-15 | Board Of Regents Of The University Of Texas System | Compositions and methods of modulating short-chain dehydrogenase activity |
EP4204002A1 (en) | 2020-08-31 | 2023-07-05 | Yale University | Compositions and methods for delivery of nucleic acids to cells |
US20220228142A1 (en) | 2020-12-17 | 2022-07-21 | Vertex Pharmaceuticals Incorporated | Compositions and methods for editing beta-globin for treatment of hemaglobinopathies |
US11873485B2 (en) | 2021-01-26 | 2024-01-16 | California Institute Of Technology | Allosteric conditional guide RNAs for cell-selective regulation of CRISPR/Cas |
WO2022239720A1 (ja) | 2021-05-10 | 2022-11-17 | 公益財団法人川崎市産業振興財団 | 抗原への結合親和性を低減させた抗体 |
WO2022261115A1 (en) | 2021-06-07 | 2022-12-15 | Yale University | Peptide nucleic acids for spatiotemporal control of crispr-cas binding |
WO2024020597A1 (en) | 2022-07-22 | 2024-01-25 | The Johns Hopkins University | Dendrimer-enabled targeted intracellular crispr/cas system delivery and gene editing |
WO2024081736A2 (en) | 2022-10-11 | 2024-04-18 | Yale University | Compositions and methods of using cell-penetrating antibodies |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4714680B1 (en) * | 1984-02-06 | 1995-06-27 | Univ Johns Hopkins | Human stem cells |
US5087570A (en) * | 1988-05-10 | 1992-02-11 | Weissman Irving L | Homogeneous mammalian hematopoietic stem cell composition |
US5061620A (en) * | 1990-03-30 | 1991-10-29 | Systemix, Inc. | Human hematopoietic stem cell |
US5147784A (en) * | 1990-04-12 | 1992-09-15 | Systemix, Inc. | T-lymphocyte progenitor cell assay |
WO1995005843A1 (en) * | 1993-08-25 | 1995-03-02 | Systemix, Inc. | Method for producing a highly enriched population of hematopoietic stem cells |
US5468612A (en) * | 1993-11-19 | 1995-11-21 | Cytomed, Inc. | 9804 gene and methods of use thereof |
-
1994
- 1994-11-14 US US08/340,047 patent/US5677136A/en not_active Expired - Lifetime
-
1995
- 1995-11-13 AT AT95935547T patent/ATE447009T1/de not_active IP Right Cessation
- 1995-11-13 AU AU37527/95A patent/AU3752795A/en not_active Abandoned
- 1995-11-13 EP EP95935547A patent/EP0787181B1/en not_active Expired - Lifetime
- 1995-11-13 DE DE69536014T patent/DE69536014D1/de not_active Expired - Fee Related
- 1995-11-13 WO PCT/IB1995/001003 patent/WO1996015229A1/en active Application Filing
- 1995-11-13 CA CA002203525A patent/CA2203525A1/en not_active Abandoned
- 1995-11-13 JP JP51588396A patent/JP3779323B2/ja not_active Expired - Fee Related
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008507957A (ja) * | 2004-07-28 | 2008-03-21 | ユニベルシテ・ルネ・デカルト・パリ 5 | 血管幹細胞及びその使用 |
Also Published As
Publication number | Publication date |
---|---|
AU3752795A (en) | 1996-06-06 |
US5677136A (en) | 1997-10-14 |
CA2203525A1 (en) | 1996-05-23 |
WO1996015229A1 (en) | 1996-05-23 |
EP0787181A1 (en) | 1997-08-06 |
ATE447009T1 (de) | 2009-11-15 |
DE69536014D1 (de) | 2009-12-10 |
JP3779323B2 (ja) | 2006-05-24 |
EP0787181B1 (en) | 2009-10-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3779323B2 (ja) | 造血幹細胞に富む組成物を得る方法、それ由来の組成物および使用法 | |
US5814440A (en) | Methods of obtaining compositions enriched for hematopoietic stem cells, antibodies for use therein, compositions derived therefrom and methods of use thereof | |
US5681559A (en) | Method for producing a highly enriched population of hematopoietic stem cells | |
US5665557A (en) | Method of purifying a population of cells enriched for hematopoietic stem cells populations of cells obtained thereby and methods of use thereof | |
JP3160600B2 (ja) | ヒト造血幹細胞 | |
Abo et al. | Characterization of human granular lymphocyte subpopulations expressing HNK‐1 (Leu‐7) and Leu‐11 antigens in the blood and lymphoid tissues from fetuses, neonates and adults | |
Craig et al. | Expression of Thy-1 on human hematopoietic progenitor cells. | |
Finke et al. | Characterization of the cytolytic activity of CD4+ and CD8+ tumor-infiltrating lymphocytes in human renal cell carcinoma | |
AU769903B2 (en) | Method for separating cells using immunorosettes | |
US20070067854A1 (en) | Chimeric mouse having an immune system constructed with human CD34+ cells and use thereof | |
WO1997018297A9 (en) | Functional human hematopoietic cells | |
JP2002543829A (ja) | 哺乳動物造血幹細胞のexvivoでの増殖 | |
JP2006122054A (ja) | 骨髄始原細胞および/またはリンパ系始原細胞について富化される細胞集団、ならびに製造方法および使用方法 | |
JPH09502167A (ja) | 新規な幹細胞マーカー | |
US20080095746A1 (en) | Process For Producing Hematopoietic Stem Cells Or Vascular Endothelial Precursor Cells | |
Pérez et al. | Characterisation of porcine bone marrow progenitor cells identified by the anti-c-kit (CD117) monoclonal antibody 2B8/BM | |
US7723047B2 (en) | Method for the discrimination and isolation of mammary epithelial stem and colony-forming cells | |
WO1996040874A1 (en) | Methods for obtaining compositions enriched for hematopoietic stem cells and antibodies for use therein | |
WO2000014203A1 (fr) | Procede de preparation d'une fraction de cellule contenant des cellules souches hematopoietiques | |
WO1994008039A1 (en) | Method of enrichment for human hematopoietic stem cells using c-kit | |
Olweus et al. | AC133, a novel marker for human hematopoietic stem and progenitor | |
WO1996015227A1 (en) | Methods of inducing cell death of primitive hematopoietic cells and compositions for induction thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20040601 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20040524 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20040831 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20041018 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20041201 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20050823 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20051122 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20060131 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20060302 |
|
R150 | Certificate of patent or registration of utility model |
Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100310 Year of fee payment: 4 |
|
LAPS | Cancellation because of no payment of annual fees |